Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
05/2003
05/27/2003US6569885 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569872 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/27/2003US6569863 Bicyclic heteroamatic compounds useful as LH agonists
05/27/2003US6569844 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives
05/27/2003US6569832 Use of a glucagon like peptide-1 (GLP-1) agonist
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003CA2176229C Improved interferon polymer conjugates
05/22/2003WO2003042397A2 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003WO2003042230A1 Non-aromatic heterocyclic esters of furan-2-one-esters of 17. beta.-carboxyl or 17 . beta. -carbothio glucocorticoids
05/22/2003WO2003042229A1 Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
05/22/2003WO2003042177A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003WO2003041757A2 Catheter injectable depot compositions and uses thereof
05/22/2003WO2003041741A1 Method of preventing or treating benign gynaecological disorders
05/22/2003WO2003041720A1 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
05/22/2003WO2003041718A1 Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
05/22/2003WO2003041715A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003WO2003041699A1 Storage stable thyroxine active drug formulations and methods for their production
05/22/2003WO2003041697A1 Method for treating autoimmune diseases
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041649A2 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003WO2002089802A3 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/22/2003WO2002030924A9 Quinazoline derivatives with anti-tumour activity
05/22/2003US20030096992 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/22/2003US20030096852 Inhibiting binding interaction between hGH (human growth hormone) or a mutant thereof and an hGH binding protein or receptor in mammal administering benzimidazole compound
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096012 Film-forming powder, compositions containing it, methods for their preparation and their uses
05/22/2003US20030096011 Wet milling suspension of labile agent dispersed in biocompatible polymer and solvent; drying to form solid polymer/labile agent matrix
05/22/2003US20030095997 Preferably collagen; capable of promoting formation of granulation tissue, angiogenesis, vascularization and epithelization; useful in surgical suturing.
05/22/2003CA2756866A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2467239A1 Catheter injectable depot compositions and uses thereof
05/22/2003CA2466998A1 Biocompatible polymer blends and uses thereof
05/22/2003CA2466632A1 Injectable depot compositions and uses thereof
05/22/2003CA2466519A1 Method for treating autoimmune diseases
05/22/2003CA2466115A1 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003CA2466055A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003CA2465868A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2464861A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/21/2003EP1312367A1 Heterocyclo-alkylsulfonyl pyrazolesa and their use as COX-2 inhibitors
05/21/2003EP1312363A1 Methods of treatment and kits comprising a growth hormone secretagogue
05/21/2003EP1311543A1 T cell receptor v beta-d beta-j beta sequence and methods for its detection
05/21/2003EP1311534A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds
05/21/2003EP1311533A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311532A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311298A2 System for regulating in vivo the expression of a transgene by conditional inhibition
05/21/2003EP1311297A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual
05/21/2003EP1311249A1 Transdermal therapeutic system
05/21/2003EP1311248A1 Transdermal therapeutic system for treating restless-legs-syndrome
05/21/2003EP1311239A1 Oral delivery of peptide
05/21/2003EP1192161B1 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
05/21/2003EP1144003A4 Methods and devices for delivery of agents to breast milk ducts
05/21/2003EP0942919B1 Sulphatase Inhibitors
05/21/2003CN1419552A 2-amino-3-(alkyl)-pyrimidone derivatives as GSKS beta. inhibitors
05/21/2003CN1419532A Novel fatty acid analogous
05/21/2003CN1419445A Agent and binding agent for pharmaceutical formulations with improved storage stability
05/21/2003CN1108967C Metering valve
05/20/2003US6566542 Such as 17-alpha-fluoro-11-beta-(4-(2-(1-piperidinyl) ethoxy) phenyl)-estra-1,3,5(10)-trien-3-ol for treatment of osteoporosis and cardiovascular protection; side effect reduction; provides alternative to estradiol
05/20/2003US6566372 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer
05/20/2003US6566342 Genetic engineering
05/20/2003US6566328 Administering to the patient a therapeutically effective amount of a polypeptide for therapy of patient in need of agonist effect of human growth hormone
05/20/2003US6565874 Polymeric delivery formulations of leuprolide with improved efficacy
05/20/2003US6565833 Medicinal aerosol formulation
05/15/2003WO2003040371A1 Novel g protein-coupled receptor protein and dna thereof
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040134A1 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof
05/15/2003WO2003039541A1 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body
05/15/2003WO2003039535A1 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
05/15/2003WO2003039489A2 Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
05/15/2003WO2003006063A3 Formulation comprising fulvestrant
05/15/2003WO2003000692A3 Oxytocin agonists
05/15/2003WO2002064795A3 Putative human enzymes
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002040480A3 Crf receptor antagonists and methods relating thereto
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092719 Methods and kits for treating depression or preventing deterioration of cognitive function
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092695 Hormone inhibitors; therapy for sexual disorders
05/15/2003US20030092691 Pharmaceutical composition based on micronized progesterone, method for the preparation thereof and uses thereof
05/15/2003US20030092686 Calibrating therapy dosage
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092623 Inducing proliferation of endothelial cells; use of Bv8 antagonists to treat testicular cancer and hormone dependent tumors; Bv8 is a small protein originally isolated from the skin secretions of the frog Bombina variegata
05/15/2003US20030092602 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/15/2003US20030092044 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders
05/15/2003US20030092028 Diagnosing insulin resistance in mammals; obtain fluid sample, detect insulin resistant marker, compare to control, amplified concentration of marker indicates insulin resistant
05/15/2003US20030091654 Dietetics, antidiabetic agents; using chromium complex
05/15/2003US20030091642 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091549 Antiinflammatory agents; inflammatory bowel disease; gastrointestinal disorders
1 ... 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 ... 290